Akebia Therapeutics, Inc. (AKBA) Covered Calls

Akebia Therapeutics, Inc. covered calls Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

You can sell covered calls on Akebia Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AKBA (prices last updated Tue 3:25 PM ET):

Akebia Therapeutics, Inc. (AKBA) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.12 +0.06 2.12 2.13 1.1M - 0.5
Covered Calls For Akebia Therapeutics, Inc. (AKBA)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 16 2 0.25 1.88 6.4% 93.4%
Jun 20 2 0.30 1.83 9.3% 56.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Akebia Therapeutics, Inc. is a biopharmaceutical company, which focuses on development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Its lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily oral therapy which works through the inhibition of hypoxia-inducible factor prolyl hydroxylase, leading to stabilization and increased levels of HIF and therefore improved production of hemoglobin and red blood cells. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.